To better understand the role of decreased GCase activity and develop a model for testing potential therapeutic candidates targeting GCase in genetic and idiopathic PD cases, we set out to develop and evaluate a novel preclinical GBA1 D409V KI mouse model. The gene discussed is GBA1; the disease is Parkinson disease.